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Abstract
Mitogen-activated protein kinases (MAPKs) are a group of serine/threonine kinases which are
activated in response to a diverse array of extracellular stimuli and mediate signal transduction from
the cell surface to the nucleus. It has been demonstrated that MAPKs are activated by external
stimuli including chemotherapeutic agents, growth factors and reproductive hormones in ovarian
surface epithelial cells. Thus, the MAPK signaling pathway may play an important role in the
regulation of proliferation, survival and apoptosis in response to these external stimuli in ovarian
cancer. In this article, an activation of the MAPK signaling cascade by several key reproductive
hormones and growth factors in epithelial ovarian cancer is reviewed.
Introduction
Mitogen-activated protein kinases (MAPKs) are a group of
serine/threonine kinases which are activated in response
to a diverse array of extracellular stimuli, and mediate sig-
nal transduction from the cell surface to the nucleus [1].
As illustrated in Fig. 1, three MAPK family including extra-
cellular signal-regulated kinases (ERK1 and ERK2), c-jun
terminal kinase/stress-activated protein kinases (JNK/
SAPK) and p38, have been well characterized [2–4]. In
addition, other MAPK family members, including ERK3, 4
and 5, four p38-like kinases and p57 MAPK have been
cloned, but the biological role of these MAPKs is not well
understood [2,4]. The MAPK cascade is activated via two
distinct classes of cell surface receptors, receptor tyrosine
kinases (RTKs) and G protein-coupled receptors (GPCRs).
The signals transmitted through this cascade can cause an
activation of diverse molecules which regulate cell
growth, survival and differentiation. ERK1 (p44 MAPK)
and ERK2 (p42 MAPK) activated by mitogenic stimuli are
a group of the most extensively studied members, whereas
JNK/SAPK and p38 are activated in response to stress such
as heat shock, osmotic shock, cytokines, protein synthesis
inhibitors, antioxidants, ultra-violet, and DNA-damaging
agents [5,6]. MAPK family members are directly regulated
by the kinases known as MAPK kinases (MAPKKs), which
activate the MAPKs by phosphorylation of tyrosine and
threonine residues [2,4,6]. At least seven different MAP-
KKs have been cloned and characterized [2,4]. The first
MAPKKs cloned were MAPK/ERK kinase 1 and 2 (MEK 1/
2), which specifically activate ERKs. MKK3 and 6 specifi-
cally activate p38, whereas MKK5 stimulates the phospho-
rylation of ERK5. The MKK4 and 7 are known to activate
JNK. The MAPKKs are activated by a rapidly expanding
group of kinases called MAPKK kinases (MAPKKKs),
which activate the MAPKKs by phosphorylation of serine
and threonine residues [4,6]. These include Raf-1, A-Raf,
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The MAPK signaling transduction pathways Figure 1
The MAPK signaling transduction pathways.
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B-raf, MAPK/ERK kinase 1–4 (MEKK1-4), apoptosis-stim-
ulating kinase-1 (ASK-1), and mixed lineage kinse-3
(MLK-3). The MAPKKKs may be activated by kinases
known as MAPKKK kinases (MAPKKKKs), one of which is
p21-activated kinase (PAK). In addition to these kinases,
low molecular weight GTP-binding (LMWG) proteins reg-
ulate the activity of MAPKKKs and MAPKKKKs [2,4].
There are several different families of LMWG proteins, two
of which include the Ras (N-Ras, K-Ras, and H-Ras) and
Rho (Rac 1, 2 and 3, Cdc42 and Rho A, B and C) families.
The activated MAPKs phosphorylate a large number of
both cytoplasmic and nuclear proteins, exerting their spe-
cific functions. For example, activated ERK1/2 phosphor-
ylate ternary complex factor (TCF) proteins such as Elk-1
and SAP-1, which form transcriptional complexes with
serum response factor (SRF) in the promoter region of
early response genes (e.g. c-fos, egr-1, junB) and thereby
regulate their expression [7]. As shown in Fig. 1, many of
these nuclear proteins, as a result of their ability to modu-
late expression of other proteins, are potential candidates
for critical factors involved in the cellular response to
stimuli.
It appears that the majority of ovarian tumors arise from
the ovarian surface epithelium (OSE), which is a simple
squamous-to-cuboidal mesothelium covering the ovary
[8]. As mentioned earlier, the MAPK cascade can be acti-
vated via both RTKs and GPCRs, which include the recep-
tors of growth factors, gonadotropins and gonadotropin-
releasing hormones (GnRH). In ovarian cancer cells,
MAPKs are activated and regulated by cisplatin [9], paclit-
axel [10], endothelin-1 [11] and GnRH [12] suggesting
that the MAPK signaling pathway plays an important role
in the regulation of proliferation, survival and apoptosis
in response to these external stimuli in ovarian cancer. In
this review, we summarize the activation of the MAPK and
its signaling cascade induced by hormones, growth factors
and chemotherapeutic agents in normal and (pre)neo-
plastic OSE cells.
Activation of MAPK by hormonal factors
There is increasing evidence that gonadotropin-releasing
hormone (GnRH) and its agonists (GnRHa) may play a
critical role in the inhibition of cell proliferation in gyne-
cological cancers including ovarian and endometrial can-
cers. However, their biological mechanism remains to be
uncovered. The GnRH receptor (GnRH-R) belongs to the
family of GPCRs. MAPK has been implicated in the anti-
proliferative effect of GnRHa in CaOV-3 ovarian cancer
cell line [12]. Treatment of CaOV-3 cells with GnRHa
resulted in an activation of ERK at 5 min, reached the
highest activation at 3 h and sustained until 24 h, whereas
GnRHa had no effect on the activation of the JNK. In addi-
tion, the ERK kinase was also activated and an increase in
phosphorylation of son of sevenless (Sos), and Shc was
observed following GnRHa treatment. Treatment with an
inhibitor of mitogen-activated protein/ERK kinase,
PD98059 reversed the antiproliferative effect of GnRHa
and the GnRH-induced dephosphorylation of the retino-
blastoma protein. These results indicate that an activation
of ERK may play a role in the antiproliferative effect of
GnRHa [12]. In our laboratory, we have shown that an
agonist of GnRH (D-Ala6)-GnRH, induced a biphasic pat-
tern of ERK-1/-2 activation in OVCAR-3 cells (Fig. 2). A
low concentration of GnRHa (10-10 M) resulted in a signif-
icant decrease of MAPK activity, whereas high concentra-
tions (10-7 and 10-6 M) induced an activation of MAPK
pathway in ovarian and placental cells [13]. It is of interest
to note that GnRH signaling appears to involve ERK-1/-2
phosphorylation through the activation of adenylyl
cyclase and PKC in rat luteinized ovarian tumors [14].
An involvement of gonadotropins, follicle-stimulating
hormone (FSH) and luteinizing hormone (LH), has been
proposed in the progression and metastasis of ovarian
cancer. Expression of FSH receptor (FSH-R), a member of
The effect of GnRH on ERK-1/-2 (p44/p42) activation in  ovarian cancer line Figure 2
The effect of GnRH on ERK-1/-2 (p44/p42) activation in 
ovarian cancer line. The phosphorylated form (P-MAPK) nor-
malized by total form (T-MAPK) was analyzed in a dose-
dependent manner by immunoblot analysis in OVCAR-3 cells 
treated with GnRH. Values are represented as the mean ± 
SD of three individual experiments. a, P < 0.05 versus 
untreated control. [Reproduced, permission with, from: 
Kang SK, Tai CJ, Cheng KW, Leung PC; "Gonadotropin-
releasing hormone activates mitogen-activated protein kinase 
in human ovarian and placental cells" in: Mol Cell Endocrinol 
2000, 170:143–151. Copyright from Elsevier]Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/71
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the GPCRs family, has been demonstrated in normal OSE
[15], ovarian inclusions and epithelial tumors [16], impli-
cating a potential role of FSH in these cells. Treatment
with FSH resulted in a growth-stimulation in ovarian can-
cer cells in a dose- and time-dependent manner in vitro
[16,17]. Despite these findings, the precise molecular
mechanism of FSH in terms of growth stimulation and
intracellular signaling in ovarian cancer remained
unknown. In a recent study, we have investigated the
involvement of MAPKs in the mechanism of the growth-
stimulatory effect of FSH in pre-neoplastic OSE cells [18].
Treatment with FSH (10, 100 and 1,000 ng/ml) resulted
in the MAPK activation of immortalized OSE (IOSE-29)
cells as shown in Fig. 3. The stimulatory effect of FSH in
the cellular proliferation and MAPK activation was com-
Effect of FSH in the presence or absence of PD98059 on  ERK-1/-2 (p44/p42) activation Figure 3
Effect of FSH in the presence or absence of PD98059 on 
ERK-1/-2 (p44/p42) activation. The P-MAPK normalized by 
T-MAPK was analyzed in a dose-dependent manner by 
immunoblot analysis in IOSE-29 cells treated with FSH. Data 
are shown as the means of three individual experiments, and 
are presented as the mean ± SD. a, P < 0.05 vs. untreated 
control; b, P < 0.05  vs. FSH (100 ng/ml) treatment; c, P < 
0.05 vs. PD98059 (50 µM) treatment. 1, untreated control; 2, 
FSH (10 ng/ml) treatment; 3, FSH (100 ng/ml) treatment; 4, 
FSH (1000 ng/ml) treatment; 5, FSH (100 ng/ml) treatment; 6, 
FSH (100 ng/ml) plus PD98059 (50 µM) treatment; 7, 
PD98059 (50 µM) treatment. [Reproduced, permission with, 
from: Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC; 
"Follicle-stimulating hormone activates mitogen-activated 
protein kinase in preneoplastic and neoplastic ovarian surface 
epithelial cells" in: J Clin Endocrinol Metab 2002, 87:2245–
2253. Copyright from Endocrine Society]
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Effect of FSH in the presence or absence of PD98059 on  ERK-1/-2 (p44/p42) activation Figure 4
Effect of FSH in the presence or absence of PD98059 on 
ERK-1/-2 (p44/p42) activation. The P-MAPK normalized by 
T-MAPK was analyzed in a time-dependent manner by immu-
noblot analysis in IOSE-29 cells treated with FSH. Data are 
shown as the means of three individual experiments, and are 
presented as the mean ± SD. a, P < 0.05 vs. untreated con-
trol; b, P < 0.05 vs. FSH (100 ng/ml) treatment for 10 min. 1, 
untreated control; 2, FSH (100 ng/ml) treatment for 5 min; 3, 
FSH (100 ng/ml) treatment for 10 min; 4, FSH (100 ng/ml) 
treatment for 20 min; 5, FSH (100 ng/ml) treatment for 60 
min; 6, FSH (100 ng/ml) plus PD98059 (50 µM) treatment for 
10 min; 7, PD98059 (50 µM) treatment. [Reproduced, per-
mission with, from: Choi KC, Kang SK, Tai CJ, Auersperg N, 
Leung PC; "Follicle-stimulating hormone activates mitogen-
activated protein kinase in preneoplastic and neoplastic ovar-
ian surface epithelial cells" in: J Clin Endocrinol Metab 2002, 
87:2245–2253. Copyright from Endocrine Society]
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pletely abolished in the presence of PD98059, a MEK
inhibitor (Fig. 3). In IOSE-29 cells, treatment with FSH
significantly increased MAPK activity at 5–10 min, and an
activated MAPK declined to control level after 20 min in
these cells (Fig. 4). In addition, treatment with FSH
resulted in substantial phosphorylation of Elk-1, the Ets
family transcriptional factor [18]. These results support
the hypothesis that the MAPK cascade is involved in cellu-
lar function such as growth stimulation in response to
FSH in pre-neoplastic OSE cells.
Similar to FSH, adenosine triphosphate (ATP) has been
implicated in the regulation of cell proliferation and acti-
vation of MAPK pathway in ovarian cancer cells. ATP
binds to heterotrimeric G protein-coupled P2 purinocep-
tors and extracellular ATP has been suggested to play a
role in cellular proliferation and intracellular calcium
concentrations (Ca2+) in ovarian cancer cells [19,20]. Our
recent results indicated that treatment with ATP resulted
in an activation of ERK-1/-2 in IOSE-29 cell line as seen
Fig. 5[21]. The stimulatory effect of ATP in the cellular
proliferation and MAPK activation was completely abol-
ished in the presence of PD98059 and staurosporin (a
PKC inhibitor), suggesting that the growth stimulatory
effect of ATP is mediated via PKC-dependent MAPK acti-
vation in pre-neoplastic OSE cells (Fig. 5). Treatment with
ATP resulted in substantial phosphorylation of Elk-1, fur-
ther implicating the MAPK cascade in the growth stimula-
tory effect of ATP in pre-neoplastic OSE cells [21].
Activation of MAPK by growth factors and 
cytokines
Endothelin-1 (ET-1) is a potential autocrine regulatory
factor in ovarian cancer. Treatment of OVCA 433 ovarian
cancer with ET-1 resulted in a phosphorylation of ERK-2
and mitogenic responses. The epidermal growth factor
receptor (EGF-R)/ras-dependent pathway may contribute
to the activation of MAPK/ERK-2 and mitogenic signaling
induced by ET-1 in these cells, suggesting that ET-1
induced activation of MAPK is mediated in part by signal-
ing pathways that are initiated by transactivation of the
EGF-R [11]. As autocrine regulators, lysophosphatidic
acid (LPA) and sphingosine-1-phosphate (S1P) have been
demonstrated to activate MAPK kinase (MEK) and p38
MAPK via AKT pathway in HEY ovarian cancer cells. The
kinase activity and S473 phosphorylation of Akt induced
by LPA and S1P required both MEK and p38 MAPK, and
MEK is likely to be upstream of p38 in these cells,
suggesting that the requirement for both MEK and p38 is
cell type- and stimulus-specific [22]. In rhesus ovarian sur-
face epithelial cells in culture, treatment with extracellular
calcium induced an activation of MAPK in the response to
cell proliferation in these normal cells [23]. Human inter-
leukin-8 (IL-8) rapidly activated ERK-1/-2 pathway via
stimulation of the CXCR-1/2 receptors [24]. By using
inhibitors such as genestein and herbimycin A, tyrosine
kinases have been shown to be involved in the IL-8 activa-
tion of ERK-1/-2 in SKOV-3 cells, suggesting an important
cross-talk between the chemokine and growth factor path-
ways in the migration and proliferation in ovarian cancer
cells [24].
In addition to ERK1/2, the JNK pathway has been sug-
gested to play a role in the cell proliferation and apoptosis
in ovarian cancer. For instance, treatment with tumor
necrosis factor (TNF) alpha activated ERK1/2 at 10–20
min, and a maximum threefold induction of ERK1/2
activity was observed after 1 min of treatment [25]. Inhi-
bition of TNF alpha-induced ERK1/2 activity by PD98059
was associated with induction of apoptosis in the TNF
Effect of ATP on ERK-1/-2 (p44/p42) and Elk-1 in the absence  or presence of PD98059 and staurosporin Figure 5
Effect of ATP on ERK-1/-2 (p44/p42) and Elk-1 in the absence 
or presence of PD98059 and staurosporin. To examine the 
role of ATP on MAPKs in IOSE-29, the cells were pretreated 
with 50 µM PD98059 or 0.1 µM staurosporin for 30 min, fol-
lowed by treatment with 100 µM ATP for 10 min. The P-
MAPK normalized by T-MAPK was analyzed by immunoblot 
analysis, and Elk-1, a downstream pathway of ERK-1/-2, was 
measured by in vitro MAPK assay, respectively. [Reproduced, 
permission with, from: Choi K-C, Tai C-J, Tzeng C-R, Auer-
sperg N, Leung PC; "Adenosine triphosphate (ATP) activates 
mitogen-activated protein kinases (MAPKs) in neoplastic 
ovarian surface epithelium (OSE) cells" in: Biol Reprod 2003, 
68: 309–315. Copyright from Society for the Study of 
Reproduction]
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alpha-resistant cell line UCI 101. Inhibition of TNF alpha-
induced ERK1/2 activity was accompanied by a subse-
quent transient increase in TNF alpha-induced JNK1 activ-
ity. These results indicate that ERK1/2 activity may
modulate cellular response to TNF alpha. A balance
between ERK1/2 and JNK1 activation may be pivotal in
the cellular growth and apoptosis response to TNF alpha
[25].
Activation of MAPK by chemotherapeutic 
agents
Cisplatin has been widely used as a chemotherapeutic
agent to treat ovarian cancers, although its use is some-
what limited because of cisplatin-resistance. The molecu-
lar mechanism of cisplatin-induced biological effect in
ovarian cancer is not well understood. Cisplatin caused a
late and prolonged induction of both ERK1/2 and JNK1
activity in a dose-dependent manner, whereas no signifi-
cant difference was observed in p38 activity in SKOV-3
cells [9]. These results suggest that ERK and other signal
transduction pathways may play a role in response to cis-
platin and be important for the development of new strat-
egies to enhance the therapeutic use of platinum drugs. In
cisplatin-resistant CaOV-3 and cisplatin-sensitive A2780
ovarian cancer cells, cisplatin induced an activation of
both ERK and JNK in distinct time and dose patterns [26].
Cisplatin-induced JNK activation was neither extracellular
and intracellular Ca2+-dependent nor protein kinase C-
dependent, whereas cisplatin-induced ERK activation was
extracellular and intracellular Ca2+-dependent and pro-
tein kinase C-dependent [26]. In regard to the regulation
of apoptosis by cisplatin, it has been shown that cisplatin
activated a robust apoptotic pathway involved in the acti-
vation of JNK and p38 MAPK in cisplatin-sensitive ovar-
ian cancer cells, whereas it fails to elicit the response in
cisplatin-resistant 2008/C13 cells [27]. In cisplatin-resist-
ant cells, the proteolytic activation of MEKK1 by caspase-
3 is deficient, suggesting that inadequate caspase-3
processing and MEKK1 activation may induce a cisplatin-
resistant phenotype [27].
The activation of two MAP kinases, JNK1 and ERK1/2 was
compared in the cisplatin-sensitive ovarian carcinoma cell
line A2780 and the cisplatin-resistant cell lines CP70 and
C200 [28]. Distinct patterns of cisplatin-induced JNK1
and ERK1/2 activation were observed in the cell lines with
different levels of cisplatin sensitivity, and inhibition of
cisplatin-induced ERK1/2 activation appeared to enhance
sensitivity to cisplatin in both cisplatin-sensitive and cis-
platin-resistant cell lines. It appears that these MAPK path-
ways may be important in the cisplatin-resistance in
ovarian cancer, which can be used as a potential therapeu-
tic strategy [28]. More recent data indicate that cisplatin
differentially induced JNK and p38 pathways, with the cis-
platin-sensitive cells showing prolonged (8–12 h) activa-
tion and the cisplatin-resistant cells showing only
transient (1–3 h) activation of JNK and p38 [29]. In addi-
tion, the inhibition of cisplatin-induced JNK and p38 acti-
vation blocked cisplatin-induced apoptosis and persistent
activation of JNK resulted in an increase in the phosphor-
ylation of c-Jun transcription factor, which stimulated a
transcription of an immediate downstream target, a death
inducer Fas ligand (FasL) in cisplatin-sensitive cells. Thus,
it appears that the JNK-c-Jun-FasL-Fas signaling pathway
plays an important role in the regulation of cisplatin-
induced apoptosis in ovarian cancer cells, and the dura-
tion of JNK activation may be essential in the determina-
tion of survival or apoptosis in ovarian cancer cells [29].
Taxol, a microtubule stabilizer, is a useful therapeutic
agent for ovarian cancer treatment. Treatment with taxol
resulted in an activation of ERK1/2 and p38 MAPK in
human ovarian carcinoma cells with distinct kinetics [30].
The low concentrations of taxol (1–100 nM) activated
ERK1/2 within 0.5–6 h, whereas a longer exposure (24 h)
at low concentrations abrogated ERK1/2 phosphoryla-
tion/activation. Higher concentrations (1–10 µM) of taxol
resulted in a sharp inhibition of ERK1/2 activity, whereas
same concentrations activated p38 kinase at 2 – 24 h,
indicating that the activation of MAPK may be dependent
on the dose and exposure time of chemotherapeutic agent
[30]. Interestingly, treatment with paclitaxel resulted in a
phosphorylation of p70S6K (T421/S424) and this paclit-
axel-induced phosphorylation requires both de novo RNA
and protein synthesis via multiple signaling pathways
including ERK1/2 MAP kinase, JNK, PKC, Ca(++), PI3K,
and mammalian target of rapamycin (mTOR). Thus, pacl-
itaxel is able to induce p70S6K phosphorylation and exert
its antitumor effect via multiple signaling pathways, espe-
cially inhibition of p70S6K [31].
Genes related with the activation of MAPK
The expression levels of kinases have compared in nor-
mal, immortalized and neoplastic OSE cells [32]. The
expression levels of casein kinase II (CK2), p38 MAPK,
cyclin-dependent kinase, and the phosphatidylinositol 3-
kinase (PI3K) effectors Akt2 and p70 S6 kinase (S6K) were
several-fold higher in neoplastic OSE than in normal OSE,
whereas no significant difference was observed in the
expression of ERK1/2 [32]. Interestingly, c-Jun NH2-
kinase but not PI3-K resulted in telomerase activity. An
inhibition of JNK by a specific inhibitor reversed telomer-
ase activity, while the expression of JNK induced an acti-
vation of a reporter gene fused to the hTERT promoter
sequence at transcriptional level, indicating that JNK plays
a critical role in the regulation of telomerase activity and
may provide possible therapeutic approaches to ovarian
cancer [33]. In addition, the correlation between BRCA1
and stress-associated MAPK has been proposed in ovarian
cancer cells [34]. The JNK, an apoptotic signalingReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/71
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pathway, was induced by overexpression of BRCA1, and
BRCA1 enhanced the signaling pathways that sequentially
involved H-Ras, MEKK4, JNK, Fas ligand/Fas interactions,
and caspase-9 activation [34].
Recently, it has been shown that gamma-synuclein is dra-
matically up-regulated in the vast majority of late-stage
breast and ovarian cancers and its overexpression may be
related with enhanced tumorigenicity. Furthermore, over-
expression of gamma-synuclein resulted in a constitutive
activation of ERK1/2 and down-regulation of JNK1 in
response to environmental stress signals, including UV,
arsenate and heat shock [35]. The cross-talk between the
MAPK signaling pathway and multi-drug resistant protein
MDR-1 has been suggested in terms of sensitivity or resist-
ance to chemotherapy. A constitutive activation of the
ERK1/2 pathway was observed, whereas the level of active
JNK and p38 remained unchanged in the taxol resistant
cells. Inhibition of the ERK1/2 pathway by specific inhib-
itors, UO126 or PD098059, resulted in a re-sensitization
in the taxol resistant cells [36].
There is some evidence that the MAPK pathway may play
a role in the metastasis of ovarian cancer. Treatment of
ovarian cancer cells with MEK1 inhibitors, U0126 and
PD98059, induced a significant suppression of the MMP-
9 secretion activated by fibronectin (FN), suggesting an
importance of these signaling molecules as a chemothera-
peutic target for cancer to prevent metastasis [37]. The
urokinase-type plasminogen activator receptor (u-PAR)
has been implicated in tumor progression, and the expres-
sion of this gene is strongly up-regulated by phorbol 12-
myristate 13-acetate (PMA), a PKC activator. Treatment of
the u-PAR-deficient ovarian cancer OVCAR-3 cells, which
contain low JNK activities, with PMA resulted in a rapid (5
min) activation of JNK pathway. This finding suggests that
the PMA- or c-Ha-Ras-dependent stimulation of u-PAR
gene expression requires a JNK1-dependent signaling
module [38].
Concluding Remarks
There is increasing evidence that the three well-character-
ized members of the MAPK family, ERK1/2, JNK/SAPK
and p38, play an important role in the regulation of pro-
liferation, survival and apoptosis in ovarian cancer in
response to the external stimuli including hormones,
growth factors, cytokines and chemotherapeutic
chemicals. The signaling pathways by which hormones
such as FSH, ATP and GnRH exert their effects in the reg-
ulation of cell proliferation and apoptosis in ovarian can-
cer cells are proposed in Fig. 6. As well, MAPK pathways
may contribute to the metastasis and chemoresistance of
ovarian cancer. A better understanding of the MAPK and
other signaling pathways in normal and neoplastic OSE
will provide new insights for the development of novel
therapeutic approach to ovarian cancer.
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